Nervomax is a newly-developed drug that functions to increase the contraction and performance of muscle physiology through the stimulation of receptors. The drug is able to intervene in the process of the breakdown of organic chemicals that are associated with neurotransmission throughout the body (Moroz et al., 2021). This allows Nervomax to stimulate selected receptors without crossing the brain-blood barrier in order to engage with the central nervous system. The second process that occurs after the intervention with the organic chemicals is the blocking of particular enzymes in order to allow the organic chemicals to not be broken down. This allows the neurotransmission-related chemicals to bind with more receptors and induce greater muscle contractions. Overall, Nervomax can assist with the development of muscle tone due to increased contractions. Similarly, it can reverse the effects of muscle relaxants as it triggers the opposing processes to be active.
The drug has a number of side effects outside of the immediate symptoms of muscle contraction. These can include headaches, blurred vision, allergic reactions, congestive iritis, and specific pain in the area of the forehead. Internal processes may also be affected, as Nervomax can cause a reduced heart rate, vomiting, nausea, diarrhea, anorexia, dizziness, stomach pain, sweating, seizures, and abdominal cramps. Though rarer, retinal detachment may also be one of the side effects of the drug. Allergic reactions may be common and as such, anti-allergy medication may be required when taking Nervomax. The use of the drug and the termination of its use may also lead to withdrawal symptoms, particularly tremors, loss of appetite, and nausea. Tolerability may vary between patients in relation to withdrawal, allergy-proneness, and other negative side effects of the drugs.
Reference
Moroz, L. L., Romanova, D. Y., & Kohn A. B. (2021). Neural versus alternative, integrative systems: molecular insights into origins of neurotransmitters. Philosophical Transactions of the Royal Society, 376(1821).